CA2603654C - Crystalline hydrochloride salt of a quinolinone-carboxamide compound or a solvate thereof - Google Patents

Crystalline hydrochloride salt of a quinolinone-carboxamide compound or a solvate thereof Download PDF

Info

Publication number
CA2603654C
CA2603654C CA2603654A CA2603654A CA2603654C CA 2603654 C CA2603654 C CA 2603654C CA 2603654 A CA2603654 A CA 2603654A CA 2603654 A CA2603654 A CA 2603654A CA 2603654 C CA2603654 C CA 2603654C
Authority
CA
Canada
Prior art keywords
salt form
crystalline
crystalline salt
oxo
dihydroquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2603654A
Other languages
English (en)
French (fr)
Other versions
CA2603654A1 (en
Inventor
Paul R. Fatheree
S. Derek Turner
Adam Goldblum
Robert Chao
Daniel Genov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma R&D IP LLC
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of CA2603654A1 publication Critical patent/CA2603654A1/en
Application granted granted Critical
Publication of CA2603654C publication Critical patent/CA2603654C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2603654A 2005-04-06 2006-04-05 Crystalline hydrochloride salt of a quinolinone-carboxamide compound or a solvate thereof Expired - Lifetime CA2603654C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06
US60/668,780 2005-04-06
PCT/US2006/012978 WO2006108127A2 (en) 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound

Publications (2)

Publication Number Publication Date
CA2603654A1 CA2603654A1 (en) 2006-10-12
CA2603654C true CA2603654C (en) 2014-05-27

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2603654A Expired - Lifetime CA2603654C (en) 2005-04-06 2006-04-05 Crystalline hydrochloride salt of a quinolinone-carboxamide compound or a solvate thereof

Country Status (29)

Country Link
US (4) US7728004B2 (enExample)
EP (1) EP1874766B1 (enExample)
JP (2) JP5230407B2 (enExample)
KR (1) KR101322873B1 (enExample)
CN (1) CN101151264B (enExample)
AR (2) AR053208A1 (enExample)
AT (1) ATE479682T1 (enExample)
AU (1) AU2006232129B2 (enExample)
BR (1) BRPI0610657A2 (enExample)
CA (1) CA2603654C (enExample)
CY (1) CY1111275T1 (enExample)
DE (1) DE602006016586D1 (enExample)
DK (1) DK1874766T3 (enExample)
EA (1) EA012115B1 (enExample)
ES (1) ES2350495T3 (enExample)
HR (1) HRP20100629T1 (enExample)
IL (1) IL186023A (enExample)
MA (1) MA29403B1 (enExample)
MX (1) MX2007012438A (enExample)
MY (1) MY151075A (enExample)
NO (1) NO339699B1 (enExample)
NZ (1) NZ561900A (enExample)
PE (1) PE20061310A1 (enExample)
PL (1) PL1874766T3 (enExample)
PT (1) PT1874766E (enExample)
SI (1) SI1874766T1 (enExample)
TW (1) TWI377206B (enExample)
WO (1) WO2006108127A2 (enExample)
ZA (1) ZA200708071B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
DE602005016446D1 (de) * 2004-11-05 2009-10-15 Theravance Inc 5-HT4-Rezeptoragonistenverbindungen
DE602005014566D1 (de) 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
PT2404919E (pt) 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
JP2010527357A (ja) * 2007-05-17 2010-08-12 セラヴァンス， インコーポレーテッド 腸の前処置のための運動促進剤
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
HUE049642T2 (hu) * 2007-12-07 2020-09-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
LT2419104T (lt) 2009-04-13 2018-02-12 Theravance Biopharma R&D Ip, Llc 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
CA3069989C (en) 2017-07-31 2025-05-06 Alfasigma S.P.A. METHODS FOR TREATING GASTROPARESIA SYMPTOMS USING VELUSETRAG
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
US20260124194A1 (en) 2022-09-20 2026-05-07 Alfasigma S.P.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
DE69113284T2 (de) * 1990-12-28 1996-02-22 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Chinolinderivat.
WO1994012497A1 (fr) 1992-11-20 1994-06-09 Taisho Pharmaceutical Co., Ltd. Compose heterocyclique
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
DE602005016446D1 (de) 2004-11-05 2009-10-15 Theravance Inc 5-HT4-Rezeptoragonistenverbindungen
DE602005014566D1 (de) 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
US20060183901A1 (en) 2005-02-17 2006-08-17 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
BRPI0608392A2 (pt) 2005-03-02 2009-12-29 Theravance Inc compostos de quinolinona como agonistas do receptor 5-ht4
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
JP5230407B2 (ja) 2013-07-10
WO2006108127A3 (en) 2007-01-04
PT1874766E (pt) 2010-11-30
NO339699B1 (no) 2017-01-23
JP2008535848A (ja) 2008-09-04
US7728004B2 (en) 2010-06-01
ES2350495T3 (es) 2011-01-24
NO20075574L (no) 2007-11-02
PL1874766T3 (pl) 2011-02-28
CN101151264B (zh) 2011-07-06
WO2006108127A2 (en) 2006-10-12
IL186023A (en) 2011-09-27
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
AU2006232129B2 (en) 2012-07-12
CA2603654A1 (en) 2006-10-12
EA012115B1 (ru) 2009-08-28
AR110019A2 (es) 2019-02-13
EA200702161A1 (ru) 2008-04-28
MX2007012438A (es) 2007-12-05
NZ561900A (en) 2010-12-24
CY1111275T1 (el) 2015-08-05
CN101151264A (zh) 2008-03-26
DE602006016586D1 (de) 2010-10-14
IL186023A0 (en) 2008-01-20
MA29403B1 (fr) 2008-04-01
BRPI0610657A2 (pt) 2010-07-13
US20140256769A1 (en) 2014-09-11
HK1110866A1 (en) 2008-07-25
US20100197728A1 (en) 2010-08-05
TW200643020A (en) 2006-12-16
HRP20100629T1 (hr) 2010-12-31
EP1874766A2 (en) 2008-01-09
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
KR20070116988A (ko) 2007-12-11
ZA200708071B (en) 2008-10-29
PE20061310A1 (es) 2007-01-23
JP2012153725A (ja) 2012-08-16
US20160095849A1 (en) 2016-04-07
US20060229332A1 (en) 2006-10-12
ATE479682T1 (de) 2010-09-15
AU2006232129A1 (en) 2006-10-12
KR101322873B1 (ko) 2013-10-30
US9126994B2 (en) 2015-09-08
MY151075A (en) 2014-03-31
AR053208A1 (es) 2007-04-25
SI1874766T1 (sl) 2010-12-31
TWI377206B (en) 2012-11-21

Similar Documents

Publication Publication Date Title
US9402840B2 (en) Crystalline form of a quinolinone-carboxamide compound
CA2561558C (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
EP1807423B1 (en) Quinolinone-carboxamide compounds
US8288550B2 (en) Crystalline form of a benzimidazole-carboxamide medicinal compound
US20060183901A1 (en) Crystalline form of an indazole-carboxamide compound
EP1871772B1 (en) Quinolinone compounds as 5-ht4 receptor agonists
HK1110866B (en) Crystalline form of a quinolinone-carboxamide compound

Legal Events

Date Code Title Description
EEER Examination request
R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250204

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250211

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250211

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250910

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260728